Susceptibility and Risk of SARS-COV-2 Infection Among Middle-aged and Older Adults in Tarragona Area, Spain

Overview

Journal Med Clin (Barc)

Specialty General Medicine

Date 2021 Jun 2

PMID 34074472

Citations 4

Authors

Eva M Satue-Gracia

Angel Vila-Corcoles

Cinta de Diego-Cabanes

Angel Vila-Rovira

Cristina Torrente-Fraga

Frederic Gomez-Bertomeu

Imma Hospital-Guardiola

Olga Ochoa-Gondar

Francisco Martin-Lujan

Affiliations

Soon will be listed here.

Abstract

Objective: To analyse susceptibility/risk of suffering COVID-19 among adults with distinct underlying medical conditions.

Methods: Population-based cohort study involving 79,083 individuals ≥50 years old in Tarragona (Southern Catalonia, Spain). Baseline cohort characteristics (demographic, pre-existing comorbidities, chronic medications and vaccinations history) were established at study start (01/03/2020) and primary outcome was laboratory-confirmed COVID-19 occurred among cohort members throughout 01/03/2020-30/06/2020. Risk of suffering COVID-19 was evaluated by Cox regression, estimating multivariable hazard ratios (HRs) adjusted for age/sex and pre-existing comorbidities.

Results: Across study period, 536 laboratory-confirmed COVID-19 cases were observed (mean incidence: 39.5 cases per 100,000 persons-week). In multivariable-analysis, increasing age/years (HR: 1.01; 95% CI: 1.00-1.02), nursing-home (HR: 20.19; 95% CI: 15.98-25.51), neurological disease (HR: 1.35; 95% CI: 1.03-1.77), taking diuretics (HR: 1.39; 95% CI: 1.10-1.75), antiplatelet (HR: 1.36; 95% CI: 1.05-1.76) and benzodiazepines (HR: 1.24; 95% CI: 1.00-1.53) increased risk; conversely, taking angiotensin-converting-enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00), angiotensin-receptor-blockers (HR: 0.70; 95%CI: 0.51-0.96) and statins (HR: 0.75; 95% CI: 0.58-0.96) were associated with reduced risk. Among community-dwelling individuals, pre-existing cancer, renal and cardiac disease appeared also related with an increased risk, whereas influenza vaccination was associated with reduced risk.

Conclusion: In a setting with relatively low incidence of COVID-19 across the first wave of pandemic period, increasing age, nursing-home residence and multiple comorbidities appear predisposing for COVID-19 among middle-aged/older adults. Conversely, statins, angiotensin-receptor blockers/inhibitors and influenza vaccination were related with decreased risk.

Citing Articles

[Clinical and sociodemographic characteristics and progression of SARS-CoV-2 patients in two health areas of Extremadura during the first six months of the pandemic].

Tejero-Mas M, Palmerin-Donoso A, Buitrago-Ramirez F, Perez-Caballero F, Morales-Gabardino J Aten Primaria. 2024; 57(6):103155.

PMID: 39689623 PMC: 11719368. DOI: 10.1016/j.aprim.2024.103155.

A Comparison of Changes in Health Behavior, Obesity, and Mental Health of Korean Adolescents Before and During the COVID-19 Pandemic: Online Cross-Sectional Study.

Lee M, Lee H Psychiatry Investig. 2023; 20(11):1086-1094.

PMID: 37997337 PMC: 10678147. DOI: 10.30773/pi.2023.0196.

A systemic study on the vulnerability and fatality of prostate cancer patients towards COVID-19 through analysis of the TMPRSS2, CXCL10 and their co-expressed genes.

Raza M, Mizan S Genomics Inform. 2022; 20(3):e31.

PMID: 36239108 PMC: 9576478. DOI: 10.5808/gi.22012.

Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study.

Bouillon K, Baricault B, Semenzato L, Botton J, Bertrand M, Drouin J J Am Heart Assoc. 2022; 11(12):e023357.

PMID: 35699173 PMC: 9238639. DOI: 10.1161/JAHA.121.023357.

Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.

Loader J, Taylor F, Lampa E, Sundstrom J J Am Heart Assoc. 2022; 11(11):e025289.

PMID: 35624081 PMC: 9238740. DOI: 10.1161/JAHA.122.025289.

References

Kow C, Hasan S . Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol. 2020; 134:153-155. PMC: 7419280. DOI: 10.1016/j.amjcard.2020.08.004. View

Kreutz R, Algharably E, Azizi M, Dobrowolski P, Guzik T, Januszewicz A . Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020; 116(10):1688-1699. PMC: 7184480. DOI: 10.1093/cvr/cvaa097. View

Salem M, El-Hennawy D . The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19. Med Hypotheses. 2020; 140:109752. PMC: 7194943. DOI: 10.1016/j.mehy.2020.109752. View

Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, de Diego C, Salsench E, Raga X . Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health. 2010; 10:25. PMC: 2822825. DOI: 10.1186/1471-2458-10-25. View

de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G . Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020; 20(9):1034-1042. PMC: 7228715. DOI: 10.1016/S1473-3099(20)30371-6. View

Ssentongo P, Ssentongo A, Heilbrunn E, Ba D, Chinchilli V . Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020; 15(8):e0238215. PMC: 7449476. DOI: 10.1371/journal.pone.0238215. View

Ietto G . SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis). Med Hypotheses. 2020; 141:109779. PMC: 7175879. DOI: 10.1016/j.mehy.2020.109779. View

Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N . The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020; 92(10):1915-1921. PMC: 7262275. DOI: 10.1002/jmv.25889. View

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q . Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94:91-95. PMC: 7194638. DOI: 10.1016/j.ijid.2020.03.017. View

10.

Koh W, Naing L, Chaw L, Rosledzana M, Alikhan M, Jamaludin S . What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS One. 2020; 15(10):e0240205. PMC: 7544065. DOI: 10.1371/journal.pone.0240205. View

11.

Vila-Corcoles A, Ochoa-Gondar O, Torrente-Fraga C, Vila-Rovira A, Satue-Gracia E, Hospital-Guardiola I . [Evaluation of incidence and risk profile for suffering Covid-19 infection by underlying conditions among middle-aged and older adults in Tarragona.]. Rev Esp Salud Publica. 2020; 94. PMC: 11583006. View

12.

Lipsitch M, Swerdlow D, Finelli L . Defining the Epidemiology of Covid-19 - Studies Needed. N Engl J Med. 2020; 382(13):1194-1196. DOI: 10.1056/NEJMp2002125. View

13.

Rodriguez-Molinero A, Galvez-Barron C, Minarro A, Macho O, Lopez G, Robles M . Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients. PLoS One. 2020; 15(10):e0239571. PMC: 7561079. DOI: 10.1371/journal.pone.0239571. View

14.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

15.

Vila-Corcoles A, Ochoa-Gondar O, Satue-Gracia E, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A . Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open. 2020; 10(12):e041577. PMC: 7733229. DOI: 10.1136/bmjopen-2020-041577. View

16.

Fakhroo A, Al Thani A, Yassine H . Markers Associated with COVID-19 Susceptibility, Resistance, and Severity. Viruses. 2021; 13(1). PMC: 7823574. DOI: 10.3390/v13010045. View

17.

Yusuf E, Maiwald M . COVID-19, equipoise and observational studies: a reminder of forgotten issues. Infection. 2020; 49(2):371-373. PMC: 7315903. DOI: 10.1007/s15010-020-01466-9. View

18.

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2005; 15(1):124-9. View

19.

Lippi G, Henry B . Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020; 75:107-108. PMC: 7118593. DOI: 10.1016/j.ejim.2020.03.014. View